Chemed (FRA:CXM) Equivalent Admissions #: 0.00 (As of . 20)


FRA:CXM Chemed Corp FRA:CXM
75 GF Score
Price €418.00
GF Value €571.67
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Chemed Equivalent Admissions #?

Chemed FRA:CXM -1.88% 75 Equivalent Admissions # is 0.00 as of . 20. GuruFocus rates FRA:CXM with a GF Score™ of 75/100 and a GF Value™ of €571.67 (Modestly Undervalued). The stock has 6 warning signs investors should review.

Equivalent Admissions # are a general measure used to indicate combined inpatient and outpatient volumes.

The historical rank and industry rank for Chemed's Equivalent Admissions # or its related term are showing as below:

FRA:CXM's Equivalent Admissions # is not ranked *
in the Healthcare Providers & Services industry.
Industry Median:
* Ranked among companies with meaningful Equivalent Admissions # only.

Chemed Equivalent Admissions # Historical Data

* Premium members only.

The historical data trend for Chemed's Equivalent Admissions # can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chemed Equivalent Admissions # Chart


FRA:CXM
75GF Score
Chemed Corp FRA:CXM
Equivalent Admissions # is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions
What does a Equivalent Admissions # of 0.00 mean?
Chemed (FRA:CXM) has a Equivalent Admissions # of 0.00 as of . 20. Equivalent Admissions are a general measure used to indicate combined inpatient and outpatient volumes. View historical data on Chemed and its competitors.
Is Chemed's Equivalent Admissions # too high?
Chemed's current Equivalent Admissions # is 0.00. Overall, Chemed has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Chemed's Equivalent Admissions # compare to PACS and LFST?
Chemed's Equivalent Admissions # of 0.00 can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equivalent Admissions # for a Healthcare Providers & Services company?
A good Equivalent Admissions # depends on the Healthcare Providers & Services industry context. However, Equivalent Admissions # should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equivalent Admissions # mean?
A high Equivalent Admissions # can signal that a stock is expensive relative to its fundamentals. Equivalent Admissions are a general measure used to indicate combined inpatient and outpatient volumes. View historical data on Chemed and its competitors. Chemed's current Equivalent Admissions # is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chemed stock overvalued right now?
Based on GuruFocus' analysis, Chemed (FRA:CXM) is currently considered Modestly Undervalued. The stock's GF Value™ is €571.67, compared to a current price of €418.00 — trading 26.9% below its estimated fair value. The current Equivalent Admissions # is 0.00. Chemed's overall GF Score™ is 75/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equivalent Admissions # calculated?
Equivalent Admissions # is calculated from a company's financial statements. For Chemed (FRA:CXM), the current Equivalent Admissions # is 0.00 as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Chemed (FRA:CXM) Overvalued in 2026?

Based on GuruFocus' analysis, Chemed stock appears to be undervalued. The current stock price of €418.00 is trading 26.9% below its estimated GF Value™ of €571.67. GuruFocus considers Chemed to be Modestly Undervalued.

Key valuation signals for FRA:CXM:

  • Equivalent Admissions #: 0.00
  • GF Value™: €571.67 vs. price of €418.00 (26.9% below fair value)
  • GF Score™: 75/100 with 6 warning signs

No single metric tells the full story. See the FRA:CXM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Chemed Business Description

Other Exchanges CHE:USA
Address 255 East Fifth Street, Suite 2600, Cincinnati, OH, USA, 45202-4726
Chemed Corp purchases, operates, and divests subsidiaries engaged in diverse business activities to maximize shareholder value. The company operates in the following segments: VITAS and Roto-Rooter. The VITAS segment generates the majority of the firm's revenue and provides hospice and palliative care services to patients with terminal illnesses through a network of physicians, registered nurses, home health aides, social workers, and volunteers. The Roto-Rooter segment provides plumbing, drain cleaning, water restoration, and related services to residential and commercial customers.
75GF Score

Get the complete analysis for FRA:CXM

Equivalent Admissions # is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€418.00
Price
€571.67
GF Value